OBJECTIVES: To test the hypothesis that children taking hydroxyurea who fail codeine therapy have an increase in reduced-functioning cytochrome P450 2D6 (CYP2D6) alleles. STUDY DESIGN: Children with sickle cell disease presenting to an emergency department with a pain crisis unresponsive to codeine were genotyped. The proportion of children with reduced-functioning alleles and CYP2D6 enzyme activity scores < or = 1.5, were compared, by chi2 analysis, in children taking hydroxyurea and those with mild disease. RESULTS: Of the 73 children completing the study, 42 had reduced-functioning alleles; 82% of the 27 children taking hydroxyurea had reduced-functioning alleles, versus 47% of 36 those with mild disease (P < .05). Activity scores were decreased in 78% of the children taking hydroxyurea and in 44% of those with mild disease (P < .05). The odds ratios of children taking hydroxyurea were 4.9 (95% confidence interval [CI] = 1.5 to 15.9) for having reduced-functioning alleles, and 4.4 (95% CI = 1.4 to 13.4) for having a low activity score. CONCLUSIONS: Failing codeine therapy for a pain crisis while taking hydroxyurea is associated with an increase in reduced-functioning CYP2D6 alleles. We recommend genetic analysis or trial of a non-CYP2D6 analgesic for these children.
OBJECTIVES: To test the hypothesis that children taking hydroxyurea who fail codeine therapy have an increase in reduced-functioning cytochrome P450 2D6 (CYP2D6) alleles. STUDY DESIGN:Children with sickle cell disease presenting to an emergency department with a pain crisis unresponsive to codeine were genotyped. The proportion of children with reduced-functioning alleles and CYP2D6 enzyme activity scores < or = 1.5, were compared, by chi2 analysis, in children taking hydroxyurea and those with mild disease. RESULTS: Of the 73 children completing the study, 42 had reduced-functioning alleles; 82% of the 27 children taking hydroxyurea had reduced-functioning alleles, versus 47% of 36 those with mild disease (P < .05). Activity scores were decreased in 78% of the children taking hydroxyurea and in 44% of those with mild disease (P < .05). The odds ratios of children taking hydroxyurea were 4.9 (95% confidence interval [CI] = 1.5 to 15.9) for having reduced-functioning alleles, and 4.4 (95% CI = 1.4 to 13.4) for having a low activity score. CONCLUSIONS: Failing codeine therapy for a pain crisis while taking hydroxyurea is associated with an increase in reduced-functioning CYP2D6 alleles. We recommend genetic analysis or trial of a non-CYP2D6 analgesic for these children.
Authors: C Hoppe; S Cheng; M Grow; A Silbergleit; W Klitz; E Trachtenberg; H Erlich; E Vichinsky; L Styles Journal: Br J Haematol Date: 2001-09 Impact factor: 6.998
Authors: K J Sullivan; N Kissoon; L J Duckworth; E Sandler; B Freeman; E Bayne; J E Sylvester; J J Lima Journal: Am J Respir Crit Care Med Date: 2001-12-15 Impact factor: 21.405
Authors: Henrike Wuttke; Thomas Rau; Roland Heide; Klaus Bergmann; Michael Böhm; Joachim Weil; Dierk Werner; Thomas Eschenhagen Journal: Clin Pharmacol Ther Date: 2002-10 Impact factor: 6.875
Authors: Robert L Findling; Gianluca Nucci; Antoni A Piergies; Roberto Gomeni; Edward I Bartolic; Regan Fong; David J Carpenter; J Steven Leeder; Andrea Gaedigk; Theodore M Danoff Journal: Neuropsychopharmacology Date: 2006-06 Impact factor: 7.853
Authors: Mari H Dallas; Brandon Triplett; David R Shook; Christine Hartford; Ashok Srinivasan; Joseph Laver; Russell Ware; Wing Leung Journal: Biol Blood Marrow Transplant Date: 2013-02-14 Impact factor: 5.742
Authors: Roseann S Gammal; Kristine R Crews; Cyrine E Haidar; James M Hoffman; Donald K Baker; Patricia J Barker; Jeremie H Estepp; Deqing Pei; Ulrich Broeckel; Winfred Wang; Mitchell J Weiss; Mary V Relling; Jane Hankins Journal: Pediatrics Date: 2016-07 Impact factor: 7.124